{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:38:53Z","timestamp":1790246333190,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"vor","delay-in-days":1025,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Nelia et Amadeo Barletta Foundation"},{"DOI":"10.13039\/501100004201","name":"Oncosuisse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004201","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Oncoethix","award":["KLS-3636-02-2015"],"award-info":[{"award-number":["KLS-3636-02-2015"]}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2018]]},"DOI":"10.1136\/esmoopen-2018-000387","type":"journal-article","created":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T01:04:28Z","timestamp":1538010268000},"page":"e000387","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance"],"prefix":"10.1016","volume":"3","author":[{"given":"Chiara","family":"Tarantelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bernasconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Gaudio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Cascione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Restelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto Jesus","family":"Arribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Spriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afua Adjeiwaa","family":"Mensah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Kwee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurilio","family":"Ponzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Zucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Carrassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Riveiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyvan","family":"Rezai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Stathis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Cvitkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bertoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/esmoopen-2018-000387_bb0010","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","article-title":"Mantle cell lymphoma","volume":"34","author":"Cheah","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2018-000387_bb0015","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/bjh.15283","article-title":"Guideline for the management of mantle cell lymphoma","volume":"182","author":"McKay","year":"2018","journal-title":"Br J Haematol"},{"issue":"suppl_4","key":"10.1136\/esmoopen-2018-000387_bb0020","doi-asserted-by":"crossref","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2018-000387_bb0025","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"10.1136\/esmoopen-2018-000387_bb0030","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Be\u00e0","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1136\/esmoopen-2018-000387_bb0035","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1158\/2159-8290.CD-17-0605","article-title":"BET proteins as targets for anticancer treatment","volume":"8","author":"Stathis","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1136\/esmoopen-2018-000387_bb0040","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1158\/1078-0432.CCR-14-1561","article-title":"The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs","volume":"21","author":"Boi","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1136\/esmoopen-2018-000387_bb0045","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ccr.2013.11.003","article-title":"Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma","volume":"24","author":"Chapuy","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1136\/esmoopen-2018-000387_bb0050","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1158\/1078-0432.CCR-13-3346","article-title":"Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma","volume":"21","author":"Trabucco","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1136\/esmoopen-2018-000387_bb0055","doi-asserted-by":"crossref","first-page":"11365","DOI":"10.1073\/pnas.1411701111","article-title":"Blockade of oncogenic I\u03baB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors","volume":"111","author":"Ceribelli","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1136\/esmoopen-2018-000387_bb0060","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/leu.2014.106","article-title":"Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma","volume":"28","author":"Moros","year":"2014","journal-title":"Leukemia"},{"key":"10.1136\/esmoopen-2018-000387_bb0065","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood-2015-04-639542","article-title":"Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib","volume":"126","author":"Sun","year":"2015","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2018-000387_bb0070","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/bjh.14803","article-title":"Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma","volume":"178","author":"Bernasconi","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1136\/esmoopen-2018-000387_bb0075","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(16)00021-1","article-title":"Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study","volume":"3","author":"Amorim","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1136\/esmoopen-2018-000387_bb0080","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1158\/1078-0432.CCR-17-1041","article-title":"PQR309 is a novel dual PI3K\/mTOR inhibitor with preclinical antitumor activity in lymphomas as a single agent and in combination therapy","volume":"24","author":"Tarantelli","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1136\/esmoopen-2018-000387_bb0085","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/annonc\/mdw131","article-title":"Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas","volume":"27","author":"Gaudio","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2018-000387_bb0090","doi-asserted-by":"crossref","first-page":"58142","DOI":"10.18632\/oncotarget.10983","article-title":"Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma","volume":"7","author":"Gaudio","year":"2016","journal-title":"Oncotarget"},{"key":"10.1136\/esmoopen-2018-000387_bb0095","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1080\/10428190802353591","article-title":"Preclinical versus clinical drug combination studies","volume":"49","author":"Chou","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1136\/esmoopen-2018-000387_bb0100","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1182\/blood-2013-01-475772","article-title":"Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma","volume":"122","author":"Bonetti","year":"2013","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2018-000387_bb0105","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/biostatistics\/kxj037","article-title":"Adjusting batch effects in microarray expression data using empirical Bayes methods","volume":"8","author":"Johnson","year":"2007","journal-title":"Biostatistics"},{"key":"10.1136\/esmoopen-2018-000387_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2202\/1544-6115.1027","article-title":"Linear models and Empirical Bayes methods for assessing differential expression in microarray experiments","volume":"3","author":"Smyth","year":"2004","journal-title":"Stat Appl Genet Mol Biol"},{"key":"10.1136\/esmoopen-2018-000387_bb0115","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1136\/esmoopen-2018-000387_bb0120","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.0105-2896.2006.00373.x","article-title":"A library of gene expression signatures to illuminate normal and pathological lymphoid biology","volume":"210","author":"Shaffer","year":"2006","journal-title":"Immunol Rev"},{"key":"10.1136\/esmoopen-2018-000387_bb0125","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/leu.2017.207","article-title":"BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells","volume":"32","author":"Sun","year":"2018","journal-title":"Leukemia"},{"key":"10.1136\/esmoopen-2018-000387_bb0130","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2014-05-521898","article-title":"Mantle cell lymphoma: evolving management strategies","volume":"125","author":"Campo","year":"2015","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2018-000387_bb0135","doi-asserted-by":"crossref","first-page":"37229","DOI":"10.18632\/oncotarget.5954","article-title":"Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736","volume":"6","author":"Restelli","year":"2015","journal-title":"Oncotarget"},{"key":"10.1136\/esmoopen-2018-000387_bb0140","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1136\/esmoopen-2018-000387_bb0145","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1182\/blood-2013-07-517177","article-title":"The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells","volume":"123","author":"Zhang","year":"2014","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2018-000387_bb0150","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-\u03baB-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat Med"},{"key":"10.1136\/esmoopen-2018-000387_bb0155","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hon.2251","article-title":"Concomitant high expression of Toll-like receptor (TLR) and B-cell receptor (BCR) signalling molecules has clinical implications in mantle cell lymphoma","volume":"35","author":"Akhter","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1136\/esmoopen-2018-000387_bb0160","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","article-title":"Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma","volume":"21","author":"Yang","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1136\/esmoopen-2018-000387_bb0165","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1038\/s41388-018-0194-3","article-title":"BRD4 facilitates replication stress-induced DNA damage response","volume":"37","author":"Zhang","year":"2018","journal-title":"Oncogene"},{"key":"10.1136\/esmoopen-2018-000387_bb0170","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.1038\/onc.2015.521","article-title":"BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells","volume":"35","author":"Muralidharan","year":"2016","journal-title":"Oncogene"},{"key":"10.1136\/esmoopen-2018-000387_bb0175","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.18632\/oncotarget.2583","article-title":"Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma","volume":"6","author":"Chil\u00e0","year":"2015","journal-title":"Oncotarget"},{"key":"10.1136\/esmoopen-2018-000387_bb0180","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1158\/1535-7163.MCT-16-0141","article-title":"AZD5153: a novel bivalent bet bromodomain inhibitor highly active against hematologic malignancies","volume":"15","author":"Rhyasen","year":"2016","journal-title":"Mol Cancer Ther"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292030209X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292030209X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/esmoopen-2018-000387","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:22:44Z","timestamp":1761855764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205970292030209X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"alternative-id":["S205970292030209X"],"URL":"https:\/\/doi.org\/10.1136\/esmoopen-2018-000387","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/esmoopen-2018-000387","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology; Originally published by BMJ.","name":"copyright","label":"Copyright"}],"article-number":"e000387"}}